慢性肾脏病患儿中FGF23与左心室肥厚的关联
本研究在587例轻中度慢性肾脏病(CKD)患儿中分析血浆成纤维细胞生长因子23(FGF23)与左心室肥厚(LVH)的关系。结果显示,在eGFR≥45 ml/min per 1.73 m2的患儿中,FGF23≥170 RU/ml是LVH的独立预测因素;而在eGFR<45 ml/min per 1.73 m2的患儿中未见此关联。
要点
- 在eGFR≥45的CKD患儿中,FGF23≥170 RU/ml与LVH独立相关。
- eGFR<45的患儿中FGF23与LVH无显著关联。
- FGF23可能作为早期CKD患儿心脏受累的标志物。
核心结论
- 血浆FGF23浓度≥170 RU/ml是eGFR≥45 ml/min per 1.73 m2的CKD患儿发生LVH的独立预测因素。
研究设计与样本
- 研究纳入587例轻中度CKD患儿,进行超声心动图检查和血浆C端FGF23浓度测定,采用线性和logistic回归分析。
主要发现
- 总体LVH患病率为11%。
- 在eGFR≥45 ml/min per 1.73 m2的患儿中,FGF23<100、100-169、≥170 RU/ml组的LVH患病率分别为5.4%、11.2%、15.3%(Ptrend=0.01)。
- 在该eGFR亚组中,完全调整后FGF23最高与最低类别相比的OR为3.08(95%CI 1.02-9.24,P<0.05),FGF23每倍增的OR为2.02(95%CI 1.29-3.17,P<0.01)。
- 在eGFR<45 ml/min per 1.73 m2的患儿中,FGF23与LVH无显著关联。
关键数值与推荐
- LVH定义为左心室质量指数(LVMI)≥95百分位。
- FGF23浓度分组为<100 RU/ml、100-169 RU/ml、≥170 RU/ml。
- 在eGFR≥45 ml/min per 1.73 m2的患儿中,FGF23≥170 RU/ml与LVH独立相关(完全调整OR 3.08,95%CI 1.02-9.24)。
临床怎么用
- 对于eGFR≥45 ml/min per 1.73 m2的CKD患儿,可考虑监测血浆FGF23水平以评估LVH风险。
- FGF23≥170 RU/ml提示需关注心脏结构改变,必要时进行超声心动图检查。
局限性
- 本研究为横断面分析,无法确定因果关系。
- 研究人群为轻中度CKD患儿,结论不能推广至透析或肾移植患儿。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: High plasma concentration of fibroblast growth factor 23 (FGF23) is a risk factor for left ventricular hypertrophy (LVH) in adults with CKD, and induces myocardial hypertrophy in experimental CKD. We hypothesized that high FGF23 levels associate with a higher prevalence of LVH in children with CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We performed echocardiograms and measured plasma C-terminal FGF23 concentrations in 587 children with mild-to-moderate CKD enrolled in the Chronic Kidney Disease in Children (CKiD) study. We used linear and logistic regression to analyze the association of plasma FGF23 with left ventricular mass index (LVMI) and LVH (LVMI ≥95th percentile), adjusted for demographics, body mass index, eGFR, and CKD-specific factors. We also examined the relationship between FGF23 and LVH by eGFR level. RESULTS: Median age was 12 years (interquartile range, 8-15) and eGFR was 50 ml/min per 1.73 m2 (interquartile range, 38-64). Overall prevalence of LVH was 11%. After adjustment for demographics and body mass index, the odds of having LVH was higher by 2.53 (95% confidence interval, 1.28 to 4.97; P<0.01) in participants with FGF23 concentrations ≥170 RU/ml compared with those with FGF23<100 RU/ml, but this association was attenuated after full adjustment. Among participants with eGFR≥45 ml/min per 1.73 m2, the prevalence of LVH was 5.4%, 11.2%, and 15.3% for those with FGF23 <100 RU/ml, 100-169 RU/ml, and ≥170 RU/ml, respectively (Ptrend=0.01). When eGFR was ≥45 ml/min per 1.73 m2, higher FGF23 concentrations were independently associated with LVH (fully adjusted odds ratio, 3.08 in the highest versus lowest FGF23 category; 95% confidence interval, 1.02 to 9.24; P<0.05; fully adjusted odds ratio, 2.02 per doubling of FGF23; 95% confidence interval, 1.29 to 3.17; P<0.01). By contrast, in participants with eGFR<45 ml/min per 1.73 m2, FGF23 did not associate with LVH. CONCLUSIONS: Plasma FGF23 concentration ≥170 RU/ml is an independent predictor of LVH in children with eGFR≥45 ml/min per 1.73 m2.
引用
- Mitsnefes MM, Betoko A, Schneider MF, et al. FGF23 and Left Ventricular Hypertrophy in Children with CKD. Clin J Am Soc Nephrol. 2017. PMID: 29025789. doi:10.2215/CJN.02110217
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。